CTOS 2020
Presentation - Durable Responses in Patients with Synovial Sarcoma in the Phase 1 Trial of ADP-A2M4 (MAGE-A4)
CTOS 2019
The Synovial Sarcoma Subset Analysis of the Multi-Histology Phase I Trial of ADP-A2M4 (MAGE-A4)
SITC 2020
Phase 1 Clinical Trial Evaluating the Safety of ADP-A2M10+ SPEAR T-Cells in Patients with MAGE-A10 Advanced Non-Small Cell Lung Cancer
Phase 1 Clinical Trial Evaluating the Safety of ADP-A2M10+ SPEAR T-Cells in Patients with MAGE-A10 Head and Neck, Melanoma, or Urothelial Tumors
Inhibition of AKT Signaling During Expansion of TCR-Engineered T-Cells from Patient Leukocyte Material Generates SPEAR T-Cells with Enhanced Functional Potential In Vitro
Initial Safety, Efficacy, and Product Attributes from the SURPASS Trial with ADP-A2M4CD8, a SPEAR T-Cell Therapy Incorporating an Affinity Optimized TCR Targeting MAGE-A4 and a CD8α Co-Receptor
SITC 2019
Case Reports: Correlates of Response Following Adoptive Transfer of ADP-A2M4, Affinity-Enhanced T-Cells Targeting MAGE-A4 in Synovial Sarcoma
SPEARHEAD-1 Trial Design: A Phase 2, Single-Arm, Open-Label Clinical Trial of ADP-A2M4 SPEAR T-Cells in Patients with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
SURPASS Trial Design: A Phase 1 Dose Escalation Trial to Assess Safety and Efficacy of ADP-A2M4CD8 in HLA-A2+ Patients with MAGE-A4+ Tumors
AACR 2019
Enhanced Activity of Second-Generation MAGE-A4 SPEAR T-Cells Through Co-Expression of a CD8α Homodimer
Initial Safety of AFP SPEAR T-Cells in Patients with Advanced Hepatocellular Carcinoma
AACR 2018
Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells Targeting MAGE-A4
ASCO 2020
Adaptimmune Leadership Talks About ASCO Data and Clinical Update (Video)
SPEARHEAD Trial in Progress Poster: A Phase 2 Trial of ADP-A2M4 SPEAR T-Cells in Patients with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Phase 1 Dose Escalation and Expansion Trial to Assess Safety and Efficacy of ADP-A2M4 in Advanced Solid Tumors (Presentation by Dr. David S. Hong)
ASGCT 2020
Driving ADP-A2M4 SPEAR Expression from an Endogenous Hematopoietic Lineage Promotor for “Off-the-Shelf” T-Cell Therapy for MAGE-A4+ Solid Tumors
ASGCT 2019
Differentiating T-Cells from hiPSCs to Create Off-the-Shelf SPEAR T-Cell Therapies
ILC 2020
Poster Presentation - Updated Data from Cohorts 1 and 2 of an Ongoing Study with ADP-A2AFP SPEAR T-Cells
Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T-cells (Presentation by Dr. Bruno Sangro)
Adaptimmune Leadership Talks About ADP-A2AFP data presented at the 2020 International Liver Congress (Video)
ESMO 2020
SPEARHEAD-2 Trial Design: A Phase 2 Pilot Trial of ADP-A2M4 in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Cancer